Iowa Medicaid Pharmaceutical and Therapeutics Committee
Minutes

Date: April 20, 2017

Chairperson: Stephen Richards, D.O.

Time: 9:30 a.m. to 11:25 a.m.

Location: Iowa Medicaid Enterprise, Des Moines, Iowa

Committee Members Present: Stephen Richards, D.O.; Mark Graber, M.D.; Charles Wadle, D.O.; Carole Frier, D.O.; Bruce Alexander, Pharm.D.; Jolene Kelly, PA-C; Holly Randleman, Pharm.D.; Heidi Price-Eastman, R.Ph; and Linda Gehrke, ARNP (arrived 9:50).

Iowa DHS Staff Present: Susan Parker, Pharm.D., Pharmacy Consultant

Iowa Medicaid Enterprise (IME) Staff Present: Laureen Biczak, D.O.; Erin Halverson, R.Ph.; Gina Tiernan, R.Ph.; David Smith, M.D.; and Melissa Biddle.

Managed Care Organization (MCO) Staff Present: Sandy Pranger, Amerigroup Iowa; Jennifer Schonhorst, AmeriHealth Caritas Iowa, and Karrie Hansotia, United Healthcare Plan of the River Valley.

Chairperson Stephen Richards called the meeting to order.

I. Stephen Richards asked that each committee, DHS, and IME staff member introduce themselves to the public. The November 17, 2016, open session minutes were reviewed. Mark Graber made the motion to approve the minutes, and Bruce Alexander seconded. The motion passed with no objections.

II. PDL and Drug Rebate Issues (Dr. Biczak): Changes have been made to the SSDC pool meeting schedule, to try to improve timing of offers. The states will meet via conference call for a preparatory meeting in June, and then meet again in August to make decisions about the 2018 contracts. Value-based contracts have also been discussed as a possibility going forward, as opposed to supplemental rebate contracts. However, members moving from fee-for-service to MCOs, or losing eligibility, etc. would make data analysis for value-based contracts very difficult.

III. PA Criteria/Pro-DUR Edits/Legislation (Drs. Parker and Biczak): Informational Letters 1746-MC-FFS-Dand 1769-MC-FFS-D listed changes to the Preferred Drug List (PDL), new ProDUR quantity limits, and changes to the prior authorization (PA) criteria for: Lupron Depot (Pediatric and Adult); buprenorphine/Naloxone; Short-Acting Opioids; Zinbryta; Narcan Nasal Spray; Alpha$_2$ Agonists, Extended Release; buprenorphine transdermal system and Buccal Film; Multiple Sclerosis Agents – Oral; Xolair; and Oral Constipation Agents. Informational Letter 1750-MC-FFS listed the preferred diabetic syringes, and Information Letter 1770-FFS detailed the Iowa Medicaid pharmacy reimbursement rules. Informational Letter 1755-D notified providers that all ordering referring prescribers are now required to be enrolled with Iowa Medicaid. Informational Letter 1757-MC-FFS explained ProDUR edits on Antipsychotic medications that were implemented March 1, 2017, while Informational Letter 1783-MC-FFS

notified providers of the dispensing fee change to $10.02 retroactively effective to August 1, 2016. Additionally, providers received a faxed notification regarding a POS system maintenance window. The committee also received copies of the letters sent to the Department of Human Services from the DUR Commission after their December, February, and April meetings, which included ProDUR quantity limits for some oral and topical GI agents, as well as recommended criteria for: Xolair; Oral Constipation Agents; Multiple Sclerosis Agents – Oral; Alpha$_2$ Agonists, Extended-Release; Zinbryta; Narcan Nasal Spray; buprenorphine transdermal system and Buccal Film; Insulin, Pre-filled Pens; Hepatitis C Treatments; Exondys 51; and Orkambi. The Iowa legislature is still working on the appropriations bill. Dr. Biczak discussed biological products, specifically biosimilar versus interchangeable designations, and how House File 305 would affect them going forward. There are 4 medications that qualify thus far.

IV. IME Updates: There was nothing additional to those already mentioned above.

V. Public Comment: The public speakers were:

Name	Representing	Drug/Topic
CoraLynn Trewet	Sanofi	Soliqua 100/33
Sherry Andes	Acadia	Nuplazid
Joshua Selsby	NIH, USDA, Muscular Dystrophy Association, Ryan's Quest, Michael's Cause	Exondys 51
Melanie Brenner	Opco Health	Rayaldee
Elizabeth Smyth	Sarepta	Exondys 51

At 10:15, motion to go to closed session was made by Mark Graber and seconded by Jolene Kelly. The motion passed with unanimous approval. Open session resumed at 10:52.

VI. PDL Discussion and Deliberation (Dr. Biczak): All subsequent recommendations were made to maximize cost savings to the program unless otherwise noted. Recommended changes are as follows: Eliquis to preferred; Gris-PEG to non-preferred with conditions; Generess FE Chewable tablets to preferred; norethindrone acetate and ethinyl estradiol 1mg-20mcg tablets to preferred; and norethindrone acetate and ethinyl estradiol 1.5mg-30mcg tablets to preferred. Bruce Alexander motioned to accept the recommendations above, and Chuck Wadle seconded. The decision was unanimous.

VII. Newly Released Drugs (Dr. Biczak): All following recommendations were made to maximize cost savings to the program unless otherwise noted. Dr. Biczak reviewed the new drugs, and then the committee voted unanimously in favor of all the recommendations, with individual motions as follows: Chuck Wadle motioned to make Adlyxin non-preferred with conditions, and Holly Randleman seconded. Bruce Alexander motioned to make Exondys 51 non-preferred, and Chuck Wadle seconded. Chuck Wadle motioned to make Nuplazid non-preferred, and Bruce Alexander and Jolene Kelly both seconded simultaneously. Mark Graber motioned to make Rayaldee non-preferred, and Bruce Alexander seconded. Carole Frier motioned to make Zurampic non-preferred, and Linda Gehrke and Mark Graber both seconded simultaneously.

VIII. Newly Released Generic Drugs and New Drug Dosage Forms/Strengths/Combinations (Dr. Biczak): All following recommendations were made to maximize cost savings to the program unless otherwise noted. Here is a breakdown of the PDL statuses for these new drugs: abacavir-lanivudine, preferred; amlodipine-olmesartan, preferred with conditions; aprepitant, non-preferred with conditions; drosperinone-ethinyl estradiol-levomefolate, non-preferred; ezetimibe, non-preferred; levalbuterol tartrate, non-preferred with conditions; lopinavir-ritonavir, preferred; mesalamine DR tablets, non-preferred; olmesartan, non-preferred with conditions; olmesartan-amlodipine-hctz, non-preferred with conditions; olmesartan-hctz, non-preferred with conditions; oseltamivir, non-preferred; quetiapine er, non-preferred step 3; rasagiline, non-preferred; tigecycline, non-preferred; yuvafem, non-preferred; Basaglar KwikPen, non-preferred with conditions; BromSite, non-preferred; Cuvitru, non-preferred; GoNitro, non-preferred; Inflectra, non-preferred with conditions; Invokamet XR, non-preferred with conditions; Mytesi (formerly known as Fulyzaq), non-preferred; Prestalia, non-preferred; Soliqua, non-preferred with conditions; Tolak, non-preferred; and Yosprala, non-preferred. Carole Frier motioned to accept the above recommendations. Mark Graber seconded the motion, and all members were in favor

IX. Future Meeting Locations: Carol Frier proposed that future P&T Meetings be held at locations other than the Capitol, as guns are now allowed to be carried on Capitol grounds per recent legislation. The other members agreed with that logic, and Erin Halverson said that would be taken into consideration.

A motion was made by Mark Graber to adjourn the meeting, and all in attendance approved. The meeting adjourned at 11:25 a.m. The next scheduled meeting is tentatively set for August 17, 2017.